Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of deferasirox film-coated tablet versus phlebotomy in hereditary hemochromatosis
2016-002529-12Phase 2Active
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of deferasirox in hereditary hemochromatosis (HH) (2 arms), sponsored by Novartis. Primary endpoint: Proportion of patients achieving target serum ferritin ≤100 μg/L for the first time. Started Aug 2017; status: active.
02
Drugs
deferasirox
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on 2016-002529-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002529-12.